financetom
Business
financetom
/
Business
/
Vodafone Idea says IUC not a consumer pricing matter after Reliance Jio levies charges on calls outside its network
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Vodafone Idea says IUC not a consumer pricing matter after Reliance Jio levies charges on calls outside its network
Oct 10, 2019 7:11 AM

Vodafone Idea has said that Reliance Jio’s decision to levy interconnect usage charge or IUC for outgoing calls to rival networks will not affect its customers and that it doesn’t plan to separately bill its customers for the calls they make outside its own network.

Reliance Jio on Wednesday announced plans to levy a charge of Rs 0.06 per minute as IUC for calls that its customers make to other networks.

“The announcement by one of the telecom service providers today to charge for calls made to other service providers to cover the termination charge of IUC is not only an action of undue haste but it also does not bring out the fact that interconnect is a settlement between operators and not a consumer pricing matter,” Vodafone Idea said in a statement shared with News18.

Vodafone Idea added that any decision on the matter will be taken by the Telecom Regulatory Authority of India (Trai).

“In our view, its TRAI’s call for a consultation on IUC keeping in mind the continuing asymmetry in traffic and in line with its earlier stated position on the matter.”

The statement added: “This announcement comes closely to the action taken recently to potentially hurt revenues of other operators with its recent unilateral action of reducing ringing time.”

The Vodafone Idea statement said that it continues to serve its customers in remote areas of the country despite it being an unprofitable operation.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Ross Stores Adds 40 New Locations
Ross Stores Adds 40 New Locations
Oct 13, 2025
09:13 AM EDT, 10/13/2025 (MT Newswires) -- Ross Stores ( ROST ) said Monday it recently opened 36 Ross Dress for Less and four dd's Discount across 17 different US states between September and October. The new store locations complete the company's fiscal 2025 growth plans, with the addition of 90 new store locations throughout the year, Ross Stores (...
NioCorp Developments Prices $150.2 Million Equity Offering
NioCorp Developments Prices $150.2 Million Equity Offering
Oct 13, 2025
09:13 AM EDT, 10/13/2025 (MT Newswires) -- NioCorp Developments ( NB ) said Monday it has priced a direct offering of up to about 16.1 million shares or pre-funded warrants at $9.34 per share, for gross proceeds of around $150.2 million. The offering is expected to close on Wednesday, the company said. NioCorp said it plans to use net proceeds...
Market Chatter: KKR Opposes Plan to Merge FiberCop With Rival Open Fiber
Market Chatter: KKR Opposes Plan to Merge FiberCop With Rival Open Fiber
Oct 13, 2025
09:05 AM EDT, 10/13/2025 (MT Newswires) -- KKR (KKR) is opposing Italy's attempts to combine landline network operator FiberCop and its rival Open Fiber into a unified broadband network under state oversight, Reuters reported Monday, citing four sources close to the matter. FiberCop was spun off from Telecom Italia in a 19 billion euro ($22 billion) deal last year led...
Immutep Completes Dosage Optimization Requirements for Potential Lung Cancer Immunotherapy
Immutep Completes Dosage Optimization Requirements for Potential Lung Cancer Immunotherapy
Oct 13, 2025
09:08 AM EDT, 10/13/2025 (MT Newswires) -- Immutep ( IMMP ) said Monday it received positive and straightforward feedback from the US Food and Drug Administration regarding successful completion of Project Optimus dosing requirements and agreement on 30 milligrams as the best dosage for its cancer immunotherapy eftilagimod alfa. The agreement will help in future clinical development of the therapy,...
Copyright 2023-2026 - www.financetom.com All Rights Reserved